Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $1,793,600.00 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 18,880 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $95.00, for a total value of $1,793,600.00. Following the completion of the sale, the chief executive officer directly owned 824,039 shares in the company, valued at approximately $78,283,705. This represents a 2.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $99.84 on Monday. The firm has a market capitalization of $6.22 billion, a P/E ratio of -75.07 and a beta of 2.23. The stock has a fifty day moving average price of $67.01 and a two-hundred day moving average price of $51.57. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $104.23. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. During the same quarter in the prior year, the firm posted ($0.66) EPS. The firm’s revenue for the quarter was up 19.3% on a year-over-year basis. As a group, analysts anticipate that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a report on Monday, June 15th. TD Cowen increased their price target on Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Robert W. Baird raised their price target on Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Guggenheim lifted their price objective on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Finally, Leerink Partners set a $80.00 price objective on Twist Bioscience in a research note on Friday, May 22nd. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.60.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Quarry LP acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at $28,000. Western Wealth Management LLC bought a new stake in shares of Twist Bioscience during the first quarter worth $31,000. Strs Ohio bought a new position in Twist Bioscience in the first quarter valued at about $33,000. Strategic Advocates LLC boosted its holdings in Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after acquiring an additional 906 shares during the last quarter. Finally, SBI Securities Co. Ltd. boosted its holdings in Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after acquiring an additional 571 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.